Pyronaridine Tetraphosphate
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 527036

CAS#: 76748-86-2

Description: Pyronaridine Tetraphosphate is an antimalarial agent, blocking B-hematin formation, inhibiting P-glycoprotein mediated drug resistance, and also inhibiting Ebola virus (EBOV).


Chemical Structure

img
Pyronaridine Tetraphosphate
CAS# 76748-86-2

Theoretical Analysis

MedKoo Cat#: 527036
Name: Pyronaridine Tetraphosphate
CAS#: 76748-86-2
Chemical Formula: C14H17N2O11P
Exact Mass: 420.057
Molecular Weight: 420.2668
Elemental Analysis: C, 40.01; H, 4.08; N, 6.67; O, 41.88; P, 7.37

Price and Availability

Size Price Availability Quantity
50.0mg USD 235.0 2 Weeks
100.0mg USD 390.0 2 Weeks
250.0mg USD 615.0 2 Weeks
Bulk inquiry

Synonym: Pyronaridine Tetraphosphate

IUPAC/Chemical Name: Pyronaridine phosphate

InChi Key: XBTXQAIQZLVVRR-IAIGYFSYSA-N

InChi Code: InChI=1S/C9H13N2O9P.C5H4O2/c12-5-1-2-11(9(15)10-5)8-7(14)6(13)4(20-8)3-19-21(16,17)18;6-5-3-1-2-4-7-5/h1-2,4,6-8,13-14H,3H2,(H,10,12,15)(H2,16,17,18);1-4H/t4-,6-,7-,8-;/m1./s1

SMILES Code: O=C1C=CC=CO1.O[C@@H]([C@H]([C@H](N2C(NC(C=C2)=O)=O)O3)O)[C@H]3COP(O)(O)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 420.2668 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mahotorn K, Tan-Ariya P, Thita T, Ruang-Areerate T, Sittichot N, Suwandittakul N, Mungthin M. In Vitro Sensitivity of Pyronaridine in Thai Isolates of Plasmodium falciparum. Am J Trop Med Hyg. 2017 Oct 23. doi: 10.4269/ajtmh.17-0286. [Epub ahead of print] PubMed PMID: 29141758.

2: Rizk MA, El-Sayed SAE, AbouLaila M, Eltaysh R, Yokoyama N, Igarashi I. Performance and consistency of a fluorescence-based high-throughput screening assay for use in Babesia drug screening in mice. Sci Rep. 2017 Oct 16;7(1):12774. doi: 10.1038/s41598-017-13052-5. PubMed PMID: 29038534; PubMed Central PMCID: PMC5643553.

3: Blessborn D, Kaewkhao K, Song L, White NJ, Day NPJ, Tarning J. Quantification of the antimalarial drug pyronaridine in whole blood using LC-MS/MS - Increased sensitivity resulting from reduced non-specific binding. J Pharm Biomed Anal. 2017 Nov 30;146:214-219. doi: 10.1016/j.jpba.2017.08.023. Epub 2017 Aug 26. PubMed PMID: 28886522; PubMed Central PMCID: PMC5637160.

4: Fall B, Madamet M, Diawara S, Briolant S, Wade KA, Lo G, Nakoulima A, Fall M, Bercion R, Kounta MB, Amalvict R, Benoit N, Gueye MW, Diatta B, Wade B, Pradines B. Ex vivo activity of Proveblue, a methylene blue, against field isolates of Plasmodium falciparum in Dakar, Senegal from 2013-2015. Int J Antimicrob Agents. 2017 Aug;50(2):155-158. doi: 10.1016/j.ijantimicag.2017.03.019. Epub 2017 Jul 6. PubMed PMID: 28689867.

5: Clark RL. Animal Embryotoxicity Studies of Key Non-Artemisinin Antimalarials and Use in Women in the First Trimester. Birth Defects Res. 2017 Aug 15;109(14):1075-1126. doi: 10.1002/bdr2.1035. Epub 2017 Jun 24. Review. Erratum in: Birth Defects Res. 2017 Nov 15;109 (19):1605. PubMed PMID: 28646540.

6: Saganuwan SA. Functional Chemical Groups that May Likely Become a Source for the Synthesis of Novel Central Nervous System (CNS) Acting Drugs. Cent Nerv Syst Agents Med Chem. 2017;17(3):178-186. doi: 10.2174/1871524917666170502153752. PubMed PMID: 28464765.

7: Kemirembe K, Cabrera M, Cui L. Interactions between tafenoquine and artemisinin-combination therapy partner drug in asexual and sexual stage Plasmodium falciparum. Int J Parasitol Drugs Drug Resist. 2017 Aug;7(2):131-137. doi: 10.1016/j.ijpddr.2017.03.002. Epub 2017 Mar 11. PubMed PMID: 28319724; PubMed Central PMCID: PMC5358947.

8: Diawara S, Madamet M, Kounta MB, Lo G, Wade KA, Nakoulima A, Bercion R, Amalvict R, Gueye MW, Fall B, Diatta B, Pradines B. Confirmation of Plasmodium falciparum in vitro resistance to monodesethylamodiaquine and chloroquine in Dakar, Senegal, in 2015. Malar J. 2017 Mar 16;16(1):118. doi: 10.1186/s12936-017-1773-4. PubMed PMID: 28302108; PubMed Central PMCID: PMC5356232.

9: Wang Y, Zhang Z, Xu S, Wang F, Shen Y, Huang S, Guo S. pH, redox and photothermal tri-responsive DNA/polyethylenimine conjugated gold nanorods as nanocarriers for specific intracellular co-release of doxorubicin and chemosensitizer pyronaridine to combat multidrug resistant cancer. Nanomedicine. 2017 Jul;13(5):1785-1795. doi: 10.1016/j.nano.2017.01.014. Epub 2017 Feb 6. PubMed PMID: 28185939.

10: Gendrot M, Diawara S, Madamet M, Kounta MB, Briolant S, Wade KA, Fall M, Benoit N, Nakoulima A, Amalvict R, Diémé Y, Fall B, Wade B, Diatta B, Pradines B. Association between Polymorphisms in the Pfmdr6 Gene and Ex Vivo Susceptibility to Quinine in Plasmodium falciparum Parasites from Dakar, Senegal. Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e01183-16. doi: 10.1128/AAC.01183-16. Print 2017 Mar. PubMed PMID: 28052850; PubMed Central PMCID: PMC5328570.

11: Zeng W, Bai Y, Wang M, Wang Z, Deng S, Ruan Y, Feng S, Yang Z, Cui L. Significant Divergence in Sensitivity to Antimalarial Drugs between Neighboring Plasmodium falciparum Populations along the Eastern Border of Myanmar. Antimicrob Agents Chemother. 2017 Jan 24;61(2). pii: e01689-16. doi: 10.1128/AAC.01689-16. Print 2017 Feb. PubMed PMID: 27919892; PubMed Central PMCID: PMC5278693.

12: Rizk MA, El-Sayed SA, AbouLaila M, Tuvshintulga B, Yokoyama N, Igarashi I. Large-scale drug screening against Babesia divergens parasite using a fluorescence-based high-throughput screening assay. Vet Parasitol. 2016 Aug 30;227:93-7. doi: 10.1016/j.vetpar.2016.07.032. Epub 2016 Jul 30. PubMed PMID: 27523944.

13: Gendrot M, Fall B, Madamet M, Fall M, Wade KA, Amalvict R, Nakoulima A, Benoit N, Diawara S, Diémé Y, Diatta B, Wade B, Pradines B. Absence of Association between Polymorphisms in the RING E3 Ubiquitin Protein Ligase Gene and Ex Vivo Susceptibility to Conventional Antimalarial Drugs in Plasmodium falciparum Isolates from Dakar, Senegal. Antimicrob Agents Chemother. 2016 Jul 22;60(8):5010-3. doi: 10.1128/AAC.03105-15. Print 2016 Aug. PubMed PMID: 27185795; PubMed Central PMCID: PMC4958203.

14: Fall B, Madamet M, Camara C, Amalvict R, Fall M, Nakoulima A, Diatta B, Diémé Y, Wade B, Pradines B. Plasmodium falciparum In Vitro Resistance to Monodesethylamodiaquine, Dakar, Senegal, 2014. Emerg Infect Dis. 2016 May;22(5):841-5. doi: 10.3201/eid2205.151321. PubMed PMID: 27088703; PubMed Central PMCID: PMC4861513.

15: Leang R, Canavati SE, Khim N, Vestergaard LS, Borghini Fuhrer I, Kim S, Denis MB, Heng P, Tol B, Huy R, Duparc S, Dondorp AM, Menard D, Ringwald P. Efficacy and Safety of Pyronaridine-Artesunate for Treatment of Uncomplicated Plasmodium falciparum Malaria in Western Cambodia. Antimicrob Agents Chemother. 2016 Jun 20;60(7):3884-90. doi: 10.1128/AAC.00039-16. Print 2016 Jul. PubMed PMID: 26926629; PubMed Central PMCID: PMC4914696.

16: Madamet M, Briolant S, Amalvict R, Benoit N, Bouchiba H, Cren J, Pradines B; French National Centre for Imported Malaria Study Group. The Plasmodium falciparum chloroquine resistance transporter is associated with the ex vivo P. falciparum African parasite response to pyronaridine. Parasit Vectors. 2016 Feb 9;9:77. doi: 10.1186/s13071-016-1358-z. PubMed PMID: 26858119; PubMed Central PMCID: PMC4746765.

17: Ayyoub A, Methaneethorn J, Ramharter M, Djimde AA, Tekete M, Duparc S, Borghini-Fuhrer I, Shin JS, Fleckenstein L. Population Pharmacokinetics of Pyronaridine in Pediatric Malaria Patients. Antimicrob Agents Chemother. 2015 Dec 14;60(3):1450-8. doi: 10.1128/AAC.02004-15. PubMed PMID: 26666916; PubMed Central PMCID: PMC4775925.

18: Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, Ekasari T, Djoko D, Basri H, Taylor WR, Duparc S, Subekti D, Elyazar I, Noviyanti R, Sudoyo H, Baird JK. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med. 2015 Dec 11;13:294. doi: 10.1186/s12916-015-0535-9. PubMed PMID: 26654101; PubMed Central PMCID: PMC4676167.

19: Sagara I, Beavogui AH, Zongo I, Soulama I, Borghini-Fuhrer I, Fofana B, Camara D, Somé AF, Coulibaly AS, Traore OB, Dara N, Kabore MJ, Thera I, Compaore YD, Sylla MM, Nikiema F, Diallo MS, Dicko A, Gil JP, Borrmann S, Duparc S, Miller RM, Doumbo OK, Shin J, Bjorkman A, Ouedraogo JB, Sirima SB, Djimdé AA. Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial. Lancet Infect Dis. 2016 Feb;16(2):189-98. doi: 10.1016/S1473-3099(15)00318-7. Epub 2015 Oct 23. PubMed PMID: 26601738; PubMed Central PMCID: PMC4726763.

20: Bélard S, Kurth F. Pyronaridine-artesunate retreatment for malaria. Lancet Infect Dis. 2016 Feb;16(2):136-7. doi: 10.1016/S1473-3099(15)00353-9. Epub 2015 Oct 23. PubMed PMID: 26601737.